| Company/Division name | Genentech |
| Parent company | Roche Holding AG |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 500 |
| Year reshoring announced: | 2026 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 2000 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Holly Springs |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals (GLP1) |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
